SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis B

Antiviral Research

Volumn 75, Issue 1, 2007, Pages 64-74

  Yuen, Lilly K W ^a   Ayres, Anna ^a   Littlejohn, Margaret ^a   Colledge, Danielle ^a   Edgely, Andrew ^b   Maskill, William J ^a   Locarnini, Stephen A ^a   Bartholomeusz, Angeline ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b Last Resort Support Pty Ltd   (Australia)

Author keywords

Data mining; Drug resistance; Hepatitis B virus; Relational database

Indexed keywords

RNA DIRECTED DNA POLYMERASE;

ARTICLE; CROSS RESISTANCE; DATA BASE; GENE SEQUENCE; GENOTYPE; HEPATITIS B; LABORATORY TEST; MEDICAL RECORD; NUCLEOTIDE SEQUENCE; ONLINE SYSTEM; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS MUTANT;

DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MUTATION; REFERENCE STANDARDS; SEQUENCE ANALYSIS, DNA; SOFTWARE DESIGN;

HEPATITIS B VIRUS;

EID: 34247191982     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.11.014     Document Type: Article

References (18)

1. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., Brosgart C., Colledge D., Edwards R., Ayres A., Bartholomeusz A., and Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
2. Ayres A., Locarnini S., and Bartholomeusz A. HBV genotyping and analysis for unique mutations. In: Hamatake R.K., and Lau J.Y.N. (Eds). Hepatitis B and D protocols (2004), Humana Press, Totowa, New Jersey 125-149
3. Bartholomeusz A., Locarnini S.A., Ayres A., Thompson G., and Sozzi V. Molecular modelling of hepatitis b virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology 40 4 Suppl. 1 (2004) 246A
4. Bartholomeusz A., Tehan B.G., and Chalmers D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivirus Ther. 9 (2004) 149-160
5. Benhamou Y., Bochet M., Thibault V., Di Martino V., Caumes E., Bricaire F., Opolon P., Katlama C., and Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30 (1999) 1302-1306 (see comments)
6. Delaney W.E., Yang H., Westland C.E., Das K., Arnold E., Gibbs C.S., Miller M.D., and Xiong S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77 (2003) 11833-11841
7. Galibert F., Mandart E., Fitoussi F., Tiollais P., and Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281 (1979) 646-650
8. Gaschen B., Kuiken C., Korber B., and Foley B. Retrieval and on-the-fly alignment of sequence fragments from the HIV database. Bioinformatics 17 (2001) 415-418
9. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., and Harrison T.J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24 (1996) 711-713
10. Locarnini S. Hepatitis B viral resistance: mechanisms and diagnosis. J. Hepatol. 39 Suppl. 1 (2003) S124-S132
11. Locarnini S., Hatzakis A., Heathcote J., Keeffe E.B., Liang T.J., Mutimer D., Pawlotsky J.M., and Zoulim F. Management of antiviral resistance in patients with chronic hepatitis B. Antivirus Ther. 9 (2004) 679-693
12. Margolis H.S., Alter M.J., and Hadler S.C. Hepatitis B: evolving epidemiology and implications for control. Semin. Liver Dis. 11 (1991) 84-92
13. Niesters H.G., De Man R.A., Pas S.D., Fries E., and Osterhaus A.D. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J. Med. Microbiol. 51 (2002) 695-699
14. Norder H., Courouce A.M., and Magnius L.O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198 (1994) 489-503
15. Rhee S.Y., Gonzales M.J., Kantor R., Betts B.J., Ravela J., and Shafer R.W. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 31 (2003) 298-303
16. Stuyver L.J., Locarnini S.A., Lok A., Richman D.D., Carman W.F., Dienstag J.L., and Schinazi R.F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33 751-757 (2001) 757
17. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., Plym M., Pokornowski K., Yu C.F., Angus P., Ayres A., Bartholomeusz A., Sievert W., Thompson G., Warner N., Locarnini S., and Colonno R.J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 48 (2004) 3498-3507
18. Torresi J., Earnest-Silveira L., Deliyannis G., Edgtton K., Zhuang H., Locarnini S.A., Fyfe J., Sozzi T., and Jackson D.C. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293 (2002) 305-313